Lead Speaker: Petra Denig, PharmD, PhD, FISPE – University Medical Center Groningen
Lead Speaker: Lotte Rasmussen, MScPharm, PhD – Syddansk Universitet
Speaker: Mina Tadrous, PharmD, PhD, MS, FISPE – University of Toronto
Speaker: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
Speaker: Björn Wettermark, MscPharm, PhD (he/him/his) – Uppsala university
Lead Speaker: Petra Denig, PharmD, PhD, FISPE – University Medical Center Groningen
### @@@ Lotte Rasmussen, MScPharm, PhD – Syddansk Universitet ### 1358115###Lead Speaker###Assistant professor###Syddansk Universitet###Lead Speaker: Lotte Rasmussen, MScPharm, PhD – Syddansk Universitet
### @@@ Mina Tadrous, PharmD, PhD, MS, FISPE – University of Toronto ### 1062862###Speaker###Assistant Professor###University of Toronto###Speaker: Mina Tadrous, PharmD, PhD, MS, FISPE – University of Toronto
### @@@ Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia ### 1655255###Speaker###Professor of Pharmacy###Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia###Speaker: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
### @@@ Björn Wettermark, MscPharm, PhD (he/him/his) – Uppsala university ### 1358174###Speaker###Professor###Uppsala university###Speaker: Björn Wettermark, MscPharm, PhD (he/him/his) – Uppsala university
### he/him/hisModerator: Juan M. Hincapie-Castillo, PharmD, MS, PhD (he/him/his) – University of North Carolina at Chapel Hill
Moderator: Caitlin Knox, PhD MPH (she/her/hers) – Regeneron Pharmaceuticals, Inc.
Speaker: Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania
Speaker: Mary Beth E. Ritchey, PhD, FISPE – Food and Drug Administration
Speaker: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
Moderator: Juan M. Hincapie-Castillo, PharmD, MS, PhD (he/him/his) – University of North Carolina at Chapel Hill
### he/him/his @@@ Caitlin Knox, PhD MPH (she/her/hers) – Regeneron Pharmaceuticals, Inc. ### 1360272###Moderator###Sr Dir, Pharmacoepidemiology###Regeneron Pharmaceuticals, Inc.###Moderator: Caitlin Knox, PhD MPH (she/her/hers) – Regeneron Pharmaceuticals, Inc.
### she/her/hers @@@ Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania ### 1359970###Speaker###Associate Professor of Medicine and Epidemiology###Perelman School of Medicine at the University of Pennsylvania###Speaker: Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania
### he/him/his @@@ Mary Beth E. Ritchey, PhD, FISPE – Food and Drug Administration ### 1991506###Speaker######Food and Drug Administration###Speaker: Mary Beth E. Ritchey, PhD, FISPE – Food and Drug Administration
### @@@ Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada ### 1358167###Speaker###Professor###Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada###Speaker: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
### he/him/hisLead Speaker: Amalia M. Issa, PhD, MPH, FISPE
Lead Speaker: Gillian Bartlett-Esquilant, PhD, FISPE – University of Missouri School of Medicine
Speaker: Stephen E. Kimmel, MD, MSCE, FISPE – University of Florida
Speaker: Anke-Hilse Maitland-van der Zee, PharmD, PhD (she/her/hers) – Amsterdam UMC
Speaker: Bruce C. Carleton, PharmD, FCP, FISPE – University of British Columbia
Lead Speaker: Amalia M. Issa, PhD, MPH, FISPE
### @@@ Gillian Bartlett-Esquilant, PhD, FISPE – University of Missouri School of Medicine ### 1086987###Lead Speaker###Associate Dean###University of Missouri School of Medicine###Lead Speaker: Gillian Bartlett-Esquilant, PhD, FISPE – University of Missouri School of Medicine
### @@@ Stephen E. Kimmel, MD, MSCE, FISPE – University of Florida ### 1359594###Speaker###Professor of Epidemiology###University of Florida###Speaker: Stephen E. Kimmel, MD, MSCE, FISPE – University of Florida
### @@@ Anke-Hilse Maitland-van der Zee, PharmD, PhD (she/her/hers) – Amsterdam UMC ### 1088169###Speaker###Professor of Precision Medicine in Respiratory Disease###Amsterdam UMC###Speaker: Anke-Hilse Maitland-van der Zee, PharmD, PhD (she/her/hers) – Amsterdam UMC
### she/her/hers @@@ Bruce C. Carleton, PharmD, FCP, FISPE – University of British Columbia ### 1046820###Speaker###Professor###University of British Columbia###Speaker: Bruce C. Carleton, PharmD, FCP, FISPE – University of British Columbia
###Lead Speaker: Natasha Pratt, PhD (she/her/hers) – U.S. Food and Drug Administration
Speaker: Christian Hampp, PhD, FISPE (he/him/his) – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Speaker: Jessica Jalbert, PhD (she/her/hers) – Regeneron
Speaker: Soko Setoguchi, MD, DrPH, FISPE – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Speaker: Ximena Camacho, MMath (she/her/hers) – UNSW Sydney
Speaker: Hui-Lee Wong, PhD (she/her/hers) – US Food and Drug Administration
Speaker: Silvia Perez-Vilar, PhD, PharmD – US Food and Drug Administration
Speaker: Olivier Humblet
Lead Speaker: Natasha Pratt, PhD (she/her/hers) – U.S. Food and Drug Administration
### she/her/hers @@@ Christian Hampp, PhD, FISPE (he/him/his) – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1360408###Speaker###Director, Pharmacoepidemiology###Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Speaker: Christian Hampp, PhD, FISPE (he/him/his) – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### he/him/his @@@ Jessica Jalbert, PhD (she/her/hers) – Regeneron ### 2015396###Speaker###Executive Director - HEOR-Epidemiology###Regeneron###Speaker: Jessica Jalbert, PhD (she/her/hers) – Regeneron
### she/her/hers @@@ Soko Setoguchi, MD, DrPH, FISPE – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ ### 1302720###Speaker###Professor of Medicine and Epidemiology###Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ###Speaker: Soko Setoguchi, MD, DrPH, FISPE – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
### @@@ Ximena Camacho, MMath (she/her/hers) – UNSW Sydney ### 1658324###Speaker###PhD candidate###UNSW Sydney###Speaker: Ximena Camacho, MMath (she/her/hers) – UNSW Sydney
### she/her/hers @@@ Hui-Lee Wong, PhD (she/her/hers) – US Food and Drug Administration ### 1358856###Speaker###Associate Director for Science###US Food and Drug Administration###Speaker: Hui-Lee Wong, PhD (she/her/hers) – US Food and Drug Administration
### she/her/hers @@@ Silvia Perez-Vilar, PhD, PharmD – US Food and Drug Administration ### 1358505###Speaker###Senior Epidemiologist###US Food and Drug Administration###Speaker: Silvia Perez-Vilar, PhD, PharmD – US Food and Drug Administration
### @@@ Olivier Humblet ### 2125427###Speaker#########Speaker: Olivier Humblet
###Lead Speaker: Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University
Speaker: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
Speaker: Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS
Lead Speaker: Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University
### he/him/his @@@ Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety ### 1061393###Speaker###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety###Speaker: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
### @@@ Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS ### 1062583###Speaker###Senior scientist###Leibniz Institute for Prevention Research and Epidemiology - BIPS###Speaker: Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS
### she/her/hersLead Speaker: Danica Marinac-Dabic, MD, PhD, MMSc, FISPE (she/her/hers) – FDA/CDRH/ Office of Clinical Evidence and Analysis
Speaker: Katherine Donegan, PhD – Medicines and Healthcare products Regulatory Agency
Lead Speaker: Danica Marinac-Dabic, MD, PhD, MMSc, FISPE (she/her/hers) – FDA/CDRH/ Office of Clinical Evidence and Analysis
### she/her/hers @@@ Katherine Donegan, PhD – Medicines and Healthcare products Regulatory Agency ### 1647043###Speaker###Head of Epidemiology###Medicines and Healthcare products Regulatory Agency###Speaker: Katherine Donegan, PhD – Medicines and Healthcare products Regulatory Agency
###Lead Speaker: Kevin Haynes, PharmD, MSCE (he/him/his) – Janssen Pharmaceuticals
Speaker: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy
Speaker: Matthew Reynolds, PhD, FISPE – Flatiron Health
Speaker: Daniel C. Beachler, PhD, MHS (he/him/his) – Carelon Research
Speaker: Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
Lead Speaker: Kevin Haynes, PharmD, MSCE (he/him/his) – Janssen Pharmaceuticals
### he/him/his @@@ Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy ### 1302758###Speaker###Head of Unit at ARS Toscana, Florence, Italy###ARS Toscana, Florence, Italy###Speaker: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy
### she/her/hers @@@ Matthew Reynolds, PhD, FISPE – Flatiron Health ### 1088323###Speaker###Vice President, Scientific Engagement###Flatiron Health###Speaker: Matthew Reynolds, PhD, FISPE – Flatiron Health
### @@@ Daniel C. Beachler, PhD, MHS (he/him/his) – Carelon Research ### 1062536###Speaker###Sr. Director, Safety & Epidemiology###Carelon Research###Speaker: Daniel C. Beachler, PhD, MHS (he/him/his) – Carelon Research
### he/him/his @@@ Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC ### 1088164###Speaker###Assistant Professor###Department of Population Health Sciences, Duke University School of Medicine, Durham, NC###Speaker: Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
### she/her/hersLead Speaker: Andrew Freedman, PhD, FISPE – DHHS/NIH/NICHD
Lead Speaker: Bruce C. Carleton, PharmD, FCP, FISPE – University of British Columbia
Speaker: Donna R. Rivera, PharmD, MSc, FISPE – Oncology Center of Excellence, US Food and Drug Administration
Speaker: Wei Zhou, MD, PhD, FISPE (he/him/his) – Eli Lilly and Company
Speaker: Geoffrey Liu, MSc, MD (he/him/his) – Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
Lead Speaker: Andrew Freedman, PhD, FISPE – DHHS/NIH/NICHD
### @@@ Bruce C. Carleton, PharmD, FCP, FISPE – University of British Columbia ### 1046820###Lead Speaker###Professor###University of British Columbia###Lead Speaker: Bruce C. Carleton, PharmD, FCP, FISPE – University of British Columbia
### @@@ Donna R. Rivera, PharmD, MSc, FISPE – Oncology Center of Excellence, US Food and Drug Administration ### 1358504###Speaker###Associate Director of Pharmacoepidemiology###Oncology Center of Excellence, US Food and Drug Administration###Speaker: Donna R. Rivera, PharmD, MSc, FISPE – Oncology Center of Excellence, US Food and Drug Administration
### @@@ Wei Zhou, MD, PhD, FISPE (he/him/his) – Eli Lilly and Company ### 1062524###Speaker###Associate Vice President###Eli Lilly and Company###Speaker: Wei Zhou, MD, PhD, FISPE (he/him/his) – Eli Lilly and Company
### he/him/his @@@ Geoffrey Liu, MSc, MD (he/him/his) – Princess Margaret Cancer Centre, University Health Network, Toronto, Canada ### 1088039###Speaker###Professor###Princess Margaret Cancer Centre, University Health Network, Toronto, Canada###Speaker: Geoffrey Liu, MSc, MD (he/him/his) – Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
### he/him/hisLead Speaker: Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health
Speaker: Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
Speaker: Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
Speaker: Mugdha Gokhale, PhD – Pfizer
Speaker: Til Stürmer, MD, PhD (he/him/his) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
Speaker: Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet
Lead Speaker: Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health
### she/her/hers @@@ Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1062592###Speaker###Associate Professor###Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill###Speaker: Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### she/her/hers @@@ Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC ### 1088164###Speaker###Assistant Professor###Department of Population Health Sciences, Duke University School of Medicine, Durham, NC###Speaker: Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
### she/her/hers @@@ Mugdha Gokhale, PhD – Pfizer ### 1088166###Speaker###Director, Value & Evidence###Pfizer###Speaker: Mugdha Gokhale, PhD – Pfizer
### @@@ Til Stürmer, MD, PhD (he/him/his) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1062525###Speaker###Professor###Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill###Speaker: Til Stürmer, MD, PhD (he/him/his) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### he/him/his @@@ Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet ### 1932107###Speaker###Postdoctoral Researcher###Karolinska Institutet###Speaker: Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet
### she/her/hersLead Speaker: Jennifer Christian, PharmD,PhD, FISPE (she/her/hers) – TargetRWE
Lead Speaker: Priscilla Velentgas, MS, PhD (she/her/hers) – Merck
Speaker: Cynthia J. Girman, DrPH FISPE – CERobs Consulting, LLC
Speaker: Anne Trontell, MPH, MD (she/her/hers) – Patient Centered Outcomes Research Institute
Speaker: Jay Park, PhD (he/him/his) – Core Clinical Sciences
Speaker: Kathleen E. Hurwitz, ScD (she/her/hers) – Target RWE
Lead Speaker: Jennifer Christian, PharmD,PhD, FISPE (she/her/hers) – TargetRWE
### she/her/hers @@@ Priscilla Velentgas, MS, PhD (she/her/hers) – Merck ### 2015422###Lead Speaker###Senior Principal Scientist###Merck###Lead Speaker: Priscilla Velentgas, MS, PhD (she/her/hers) – Merck
### she/her/hers @@@ Cynthia J. Girman, DrPH FISPE – CERobs Consulting, LLC ### 1088317###Speaker###Founder and President###CERobs Consulting, LLC###Speaker: Cynthia J. Girman, DrPH FISPE – CERobs Consulting, LLC
### @@@ Anne Trontell, MPH, MD (she/her/hers) – Patient Centered Outcomes Research Institute ### 1088318###Speaker###Associate Director, Clinical Effectiveness and Decision Science###Patient Centered Outcomes Research Institute###Speaker: Anne Trontell, MPH, MD (she/her/hers) – Patient Centered Outcomes Research Institute
### she/her/hers @@@ Jay Park, PhD (he/him/his) – Core Clinical Sciences ### 2100923###Speaker###Scientific Lead###Core Clinical Sciences###Speaker: Jay Park, PhD (he/him/his) – Core Clinical Sciences
### he/him/his @@@ Kathleen E. Hurwitz, ScD (she/her/hers) – Target RWE ### 1991710###Speaker###Director, Epidemiology###Target RWE###Speaker: Kathleen E. Hurwitz, ScD (she/her/hers) – Target RWE
### she/her/hersLead Speaker: Jenny Sun, PhD – Pfizer, Inc.
Speaker: Tamar Lasky, PhD, FISPE (she/her/hers) – US FDA
Speaker: Daniel B. Horton, MD, MSCE, FISPE (he/him/his) – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA
Speaker: Mehmet Burcu, PhD, MS (he/him/his) – Merck & Co., Inc., Rahway, NJ, United States
Speaker: Ann W. McMahon, MD, MS, FISPE – Office of Pediatric Therapeutics
Lead Speaker: Jenny Sun, PhD – Pfizer, Inc.
### @@@ Tamar Lasky, PhD, FISPE (she/her/hers) – US FDA ### 1046828###Speaker###Senior Advisor on RWE###US FDA###Speaker: Tamar Lasky, PhD, FISPE (she/her/hers) – US FDA
### she/her/hers @@@ Daniel B. Horton, MD, MSCE, FISPE (he/him/his) – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA ### 1302719###Speaker###Associate Professor of Pediatrics and Epidemiology###Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA###Speaker: Daniel B. Horton, MD, MSCE, FISPE (he/him/his) – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA
### he/him/his @@@ Mehmet Burcu, PhD, MS (he/him/his) – Merck & Co., Inc., Rahway, NJ, United States ### 1088178###Speaker###Sr. Director###Merck & Co., Inc., Rahway, NJ, United States###Speaker: Mehmet Burcu, PhD, MS (he/him/his) – Merck & Co., Inc., Rahway, NJ, United States
### he/him/his @@@ Ann W. McMahon, MD, MS, FISPE – Office of Pediatric Therapeutics ### 1142411###Speaker###Team Lead, Science and Innovation Team###Office of Pediatric Therapeutics###Speaker: Ann W. McMahon, MD, MS, FISPE – Office of Pediatric Therapeutics
###Lead Speaker: John D. Seeger, PharmD, DrPH, FISPE – Optum Epidemiology
Speaker: Jeremy A. Rassen, ScD, FISPE – Aetion
Lead Speaker: John D. Seeger, PharmD, DrPH, FISPE – Optum Epidemiology
### @@@ Jeremy A. Rassen, ScD, FISPE – Aetion ### 1062955###Speaker###Co-founder and President###Aetion###Speaker: Jeremy A. Rassen, ScD, FISPE – Aetion
###Lead Speaker: Emily W. Bratton, MSPH, PhD (she/her/hers) – IQVIA
Speaker: Laura Hester, PhD – Janssen R&D, LLC
Speaker: Xabier Garcia de Albeniz Martinez, MD, ScM, PhD – RTI Health Solutions
Speaker: Jie Li, PhD – US Food and Drug Administration
Lead Speaker: Emily W. Bratton, MSPH, PhD (she/her/hers) – IQVIA
### she/her/hers @@@ Laura Hester, PhD – Janssen R&D, LLC ### 1063349###Speaker###Director###Janssen R&D, LLC###Speaker: Laura Hester, PhD – Janssen R&D, LLC
### @@@ Xabier Garcia de Albeniz Martinez, MD, ScM, PhD – RTI Health Solutions ### 1062596###Speaker###Director, Epidemiology###RTI Health Solutions###Speaker: Xabier Garcia de Albeniz Martinez, MD, ScM, PhD – RTI Health Solutions
### @@@ Jie Li, PhD – US Food and Drug Administration ### 1062564###Speaker###Associate Director for RWE at Office of Surveillance and Epidemiology, CDER###US Food and Drug Administration###Speaker: Jie Li, PhD – US Food and Drug Administration
###Lead Speaker: Katja Taxis, MSc, PhD, FISPE – University of Groningen
Speaker: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
Speaker: Jennifer E. Isenor, BSc(Pharm), PharmD, RPh (she/her/hers) – College of Pharmacy, Dalhousie University
Lead Speaker: Katja Taxis, MSc, PhD, FISPE – University of Groningen
### @@@ Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia ### 1655255###Speaker###Professor of Pharmacy###Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia###Speaker: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
### @@@ Jennifer E. Isenor, BSc(Pharm), PharmD, RPh (she/her/hers) – College of Pharmacy, Dalhousie University ### 1991816###Speaker###Associate Professor###College of Pharmacy, Dalhousie University###Speaker: Jennifer E. Isenor, BSc(Pharm), PharmD, RPh (she/her/hers) – College of Pharmacy, Dalhousie University
### she/her/hersLead Speaker: Alicia W. Gilsenan, PhD, RPh, FISPE – RTI Health Solutions
Speaker: Tarek A. Hammad, MD, PhD, MSc, MS, FISPE – Takeda
Speaker: Juhaeri Juhaeri, PhD – Epidemiology & Benefit - Risk Evaluation, Sanofi
Speaker: Bennett S. Levitan, MD-PhD – Janssen Pharmaceuticals
Speaker: Carol Mansfield, PhD – RTI Health Solutions
Lead Speaker: Alicia W. Gilsenan, PhD, RPh, FISPE – RTI Health Solutions
### @@@ Tarek A. Hammad, MD, PhD, MSc, MS, FISPE – Takeda ### 1094009###Speaker###Vice President, Head of Medical Safety, Marketed Products, Global Patient Safety Evaluation###Takeda###Speaker: Tarek A. Hammad, MD, PhD, MSc, MS, FISPE – Takeda
### @@@ Juhaeri Juhaeri, PhD – Epidemiology & Benefit - Risk Evaluation, Sanofi ### 1094012###Speaker###VP and Global Head###Epidemiology & Benefit - Risk Evaluation, Sanofi###Speaker: Juhaeri Juhaeri, PhD – Epidemiology & Benefit - Risk Evaluation, Sanofi
### @@@ Bennett S. Levitan, MD-PhD – Janssen Pharmaceuticals ### 1647087###Speaker###Senior Director, Benefit-Risk / Epidemiology###Janssen Pharmaceuticals###Speaker: Bennett S. Levitan, MD-PhD – Janssen Pharmaceuticals
### @@@ Carol Mansfield, PhD – RTI Health Solutions ### 2086598###Speaker###Senior Economist & Head, Health Preference Assessment###RTI Health Solutions###Speaker: Carol Mansfield, PhD – RTI Health Solutions
###